Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma

Jonathan L. Kaufman, Ruben Niesvizky, Edward A. Stadtmauer, Asher A Chanan Khan, David Siegel, Heather Horne, William A. Wegener, David M. Goldenberg

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

CD74, expressed in multiple myeloma (MM), was evaluated as a target for immunotherapy with milatuzumab (a humanized anti-CD74 antibody). In a multicentre dose escalation study, 25 patients with advanced MM received milatuzumab doses of 1·5 (N = 8), 4·0 (N = 9), 8·0 (N = 4) or 16·0 mg/kg (N = 4) administered twice weekly x 4. They had a median of 5 prior treatments (17 post ≥1 stem cell transplantation) and were refractory (N = 7) or relapsed (N = 18) with generally short-lived responses to last treatment (median 4·0 months). After increasing prophylactic medications and slowing administration, infusions were well tolerated (National Cancer Institute-Common Terminology Criteria v3 toxicity Grades 1-2) with no dose-limiting toxicity at higher doses. Only one patient developed borderline positive human anti-milatuzumab antibody titres of uncertain clinical significance. Although milatuzumab was rapidly cleared from circulation with little serum accumulation and low trough levels, B-cell levels were moderately decreased with treatment (median decrease, 34%). There were no objective responses by European Group for Blood and Marrow Transplantation criteria, but 5 of 19 patients (26%) who completed treatment in this heavily pretreated and generally refractory group had stable disease for ≥3 months post-treatment (one continuing for 17 months). Disease stabilization and evidence of pharmacodynamic activity support further development for use in combination with other agents or as a drug conjugate. (Clinicaltrials.gov identifier: NCT00421525).

Original languageEnglish (US)
Pages (from-to)478-486
Number of pages9
JournalBritish Journal of Haematology
Volume163
Issue number4
DOIs
StatePublished - Nov 2013

Fingerprint

Multiple Myeloma
Monoclonal Antibodies
Anti-Idiotypic Antibodies
Therapeutics
Antibodies, Monoclonal, Humanized
National Cancer Institute (U.S.)
Stem Cell Transplantation
Terminology
Immunotherapy
B-Lymphocytes
milatuzumab
Serum
Pharmaceutical Preparations

Keywords

  • Antibody
  • CD74
  • Milatuzumab
  • Multiple myeloma
  • Phase 1 clinical trial

ASJC Scopus subject areas

  • Hematology

Cite this

Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma. / Kaufman, Jonathan L.; Niesvizky, Ruben; Stadtmauer, Edward A.; Chanan Khan, Asher A; Siegel, David; Horne, Heather; Wegener, William A.; Goldenberg, David M.

In: British Journal of Haematology, Vol. 163, No. 4, 11.2013, p. 478-486.

Research output: Contribution to journalArticle

Kaufman, Jonathan L. ; Niesvizky, Ruben ; Stadtmauer, Edward A. ; Chanan Khan, Asher A ; Siegel, David ; Horne, Heather ; Wegener, William A. ; Goldenberg, David M. / Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma. In: British Journal of Haematology. 2013 ; Vol. 163, No. 4. pp. 478-486.
@article{ff2683076cc44bedad27995791a68012,
title = "Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma",
abstract = "CD74, expressed in multiple myeloma (MM), was evaluated as a target for immunotherapy with milatuzumab (a humanized anti-CD74 antibody). In a multicentre dose escalation study, 25 patients with advanced MM received milatuzumab doses of 1·5 (N = 8), 4·0 (N = 9), 8·0 (N = 4) or 16·0 mg/kg (N = 4) administered twice weekly x 4. They had a median of 5 prior treatments (17 post ≥1 stem cell transplantation) and were refractory (N = 7) or relapsed (N = 18) with generally short-lived responses to last treatment (median 4·0 months). After increasing prophylactic medications and slowing administration, infusions were well tolerated (National Cancer Institute-Common Terminology Criteria v3 toxicity Grades 1-2) with no dose-limiting toxicity at higher doses. Only one patient developed borderline positive human anti-milatuzumab antibody titres of uncertain clinical significance. Although milatuzumab was rapidly cleared from circulation with little serum accumulation and low trough levels, B-cell levels were moderately decreased with treatment (median decrease, 34{\%}). There were no objective responses by European Group for Blood and Marrow Transplantation criteria, but 5 of 19 patients (26{\%}) who completed treatment in this heavily pretreated and generally refractory group had stable disease for ≥3 months post-treatment (one continuing for 17 months). Disease stabilization and evidence of pharmacodynamic activity support further development for use in combination with other agents or as a drug conjugate. (Clinicaltrials.gov identifier: NCT00421525).",
keywords = "Antibody, CD74, Milatuzumab, Multiple myeloma, Phase 1 clinical trial",
author = "Kaufman, {Jonathan L.} and Ruben Niesvizky and Stadtmauer, {Edward A.} and {Chanan Khan}, {Asher A} and David Siegel and Heather Horne and Wegener, {William A.} and Goldenberg, {David M.}",
year = "2013",
month = "11",
doi = "10.1111/bjh.12565",
language = "English (US)",
volume = "163",
pages = "478--486",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma

AU - Kaufman, Jonathan L.

AU - Niesvizky, Ruben

AU - Stadtmauer, Edward A.

AU - Chanan Khan, Asher A

AU - Siegel, David

AU - Horne, Heather

AU - Wegener, William A.

AU - Goldenberg, David M.

PY - 2013/11

Y1 - 2013/11

N2 - CD74, expressed in multiple myeloma (MM), was evaluated as a target for immunotherapy with milatuzumab (a humanized anti-CD74 antibody). In a multicentre dose escalation study, 25 patients with advanced MM received milatuzumab doses of 1·5 (N = 8), 4·0 (N = 9), 8·0 (N = 4) or 16·0 mg/kg (N = 4) administered twice weekly x 4. They had a median of 5 prior treatments (17 post ≥1 stem cell transplantation) and were refractory (N = 7) or relapsed (N = 18) with generally short-lived responses to last treatment (median 4·0 months). After increasing prophylactic medications and slowing administration, infusions were well tolerated (National Cancer Institute-Common Terminology Criteria v3 toxicity Grades 1-2) with no dose-limiting toxicity at higher doses. Only one patient developed borderline positive human anti-milatuzumab antibody titres of uncertain clinical significance. Although milatuzumab was rapidly cleared from circulation with little serum accumulation and low trough levels, B-cell levels were moderately decreased with treatment (median decrease, 34%). There were no objective responses by European Group for Blood and Marrow Transplantation criteria, but 5 of 19 patients (26%) who completed treatment in this heavily pretreated and generally refractory group had stable disease for ≥3 months post-treatment (one continuing for 17 months). Disease stabilization and evidence of pharmacodynamic activity support further development for use in combination with other agents or as a drug conjugate. (Clinicaltrials.gov identifier: NCT00421525).

AB - CD74, expressed in multiple myeloma (MM), was evaluated as a target for immunotherapy with milatuzumab (a humanized anti-CD74 antibody). In a multicentre dose escalation study, 25 patients with advanced MM received milatuzumab doses of 1·5 (N = 8), 4·0 (N = 9), 8·0 (N = 4) or 16·0 mg/kg (N = 4) administered twice weekly x 4. They had a median of 5 prior treatments (17 post ≥1 stem cell transplantation) and were refractory (N = 7) or relapsed (N = 18) with generally short-lived responses to last treatment (median 4·0 months). After increasing prophylactic medications and slowing administration, infusions were well tolerated (National Cancer Institute-Common Terminology Criteria v3 toxicity Grades 1-2) with no dose-limiting toxicity at higher doses. Only one patient developed borderline positive human anti-milatuzumab antibody titres of uncertain clinical significance. Although milatuzumab was rapidly cleared from circulation with little serum accumulation and low trough levels, B-cell levels were moderately decreased with treatment (median decrease, 34%). There were no objective responses by European Group for Blood and Marrow Transplantation criteria, but 5 of 19 patients (26%) who completed treatment in this heavily pretreated and generally refractory group had stable disease for ≥3 months post-treatment (one continuing for 17 months). Disease stabilization and evidence of pharmacodynamic activity support further development for use in combination with other agents or as a drug conjugate. (Clinicaltrials.gov identifier: NCT00421525).

KW - Antibody

KW - CD74

KW - Milatuzumab

KW - Multiple myeloma

KW - Phase 1 clinical trial

UR - http://www.scopus.com/inward/record.url?scp=84886407377&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886407377&partnerID=8YFLogxK

U2 - 10.1111/bjh.12565

DO - 10.1111/bjh.12565

M3 - Article

C2 - 24112026

AN - SCOPUS:84886407377

VL - 163

SP - 478

EP - 486

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 4

ER -